In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...

FDA panel rejects GSK's Blenrep combo due to severe ocular toxicity and dosing concerns in multiple myeloma trials ahead of ...

U.S. stocks appear poised for a positive opening on Friday, as strong earnings from major companies throughout the week have ...

Arizona Attorney General Kris Mayes says the pharmaceutical company GlaxoSmithKline manipulated patents to reduce ...

Proposals by Robert F. Kennedy Jr. and Bernie Sanders range from more disclosures in commercials to an outright ban.

AnaptysBio’s lead drug rosnilimab showed promise in RA, but lack of a Phase 3 plan and limited pipeline raise concerns. Find ...

Glaxosmithkline, with multiple operations in Montco, just scored a major regulatory win that could reshape how lupus ...

U.S. Senator Maggie Hassan said on Friday she is launching an investigation into British pharmaceutical giant GlaxoSmithKline ...

Simply sign up to the Pharmaceuticals sector myFT Digest -- delivered directly to your inbox. GlaxoSmithKline will apply for approval for its respiratory syncytial virus vaccine for older adults ...

As per the deal, GlaxoSmithKline will pay the vaccine maker up to $1.2 billion more if certain milestones are arrived at in Affinivax's impending clinical trials for a new pneumococcal vaccine.

GlaxoSmithKline has been called GSK for years — but the pharma company officially made the move to simplify the name this week. GlaxoSmithKline is now officially just GSK, the company announced Monday ...

GlaxoSmithKline plc (GSK) reported robust performance in 1Q22, driven by growth across all the segments and regions with continued R&D investments and a strengthening pipeline. Haleon (Spin-off) ...